ImproviNg rEnal Outcomes Following Coronary angiograPhy and/or percuTaneoUs coroNary intErventions

Recruiting now · Not applicable

Conditions studied: Contrast-Induced Acute Kidney Injury

In brief

The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and/or percutaneous coronary intervention (PCI).

Key facts

Study ID

NCT04936607

Run by

Montreal Heart Institute

People needed

1158

Starts

2021-06-28

Expected to finish

2027-07-31

Last updated by the study team

2025-12-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age ≥18 years;
• Planned coronary angiogram and/or PCI;
• Willingness to participate and to attend study visits;
• Expected life expectancy ≥6 months.

You may not qualify if…

• Cardiogenic or non-cardiogenic shock at the time of the procedure;
• Emergent procedures (e.g. STEMI);
• Iodine-based contrast media received within 2 days;
• Presence of Intra-Aortic Balloon Pump (IABP);
• Cardiac arrest within 24 hours;
• Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;
• Renal replacement therapy;
• Severe aortic or mitral disease;
• LVEF <30%.

Where it is running

• Montreal Heart Institute — Montreal, Quebec, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.